Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in the heart of Vienna, doubling the current production capabilities in the city. Furthermore, he illustrates the significance of BI to Austria and what more must be done to bolster the vibrant domestic life sciences ecosystem.
What is the current mandate of the Regional Center Vienna (RCV), and what importance does Vienna have in Boehringer Ingelheim’s global operations?
"We are very much committed to bringing innovation to Austria and play a large role in helping the nation's life sciences sector flourish."
